RESEARCH ARTICLE

A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma

Xian Wang\textsuperscript{1,2}, Shan Huang\textsuperscript{1,2}, Xiaocan Li\textsuperscript{2}, Dongrui Jiang\textsuperscript{2}, Hongzhen Yu\textsuperscript{1,2}, Qiang Wu\textsuperscript{1}, Chaobing Gao\textsuperscript{3}\(^*\), Zhengsheng Wu\textsuperscript{1}\(^*\)

\textsuperscript{1} Department of Pathology, Anhui Medical University, Hefei, Anhui, China, \textsuperscript{2} Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, \textsuperscript{3} Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

\(^*\) gcbl100111@163.com (CG); woozson@126.com (ZW)

Abstract

Papillary thyroid carcinoma (PTC) is the most common endocrine cancer with a significantly increase of the incidence recently. Several cytokines, such as thyroid peroxidase (TPO), cluster of differentiation 56 (CD56), Galectin-3, mesothelial cell (MC), cytokeratin 19 (CK19) and BRAF (B-raf) were recommended to be tested by immunohistochernistry (IHC) for a definitive diagnosis, but were still limited in clinical use because of their relative lower sensitivity and specificity. MicroRNA (miRNA), as a new molecular biomarkers, however, has not been reported yet so far. To address this, hsa-miR-200a-5p, a miRNA, was selected and detected in PTC patients by in situ hybrization with benign thyroid tumor with papillary hyperplasia as a control, and the differential expression of hsa-miR-200a-5p between fresh PTC tissues and control was detected by qRT-PCR. Expressive levels of cytokines of TPO, CD56, Galectin-3, MC, CK19 and B-raf were also detected by immunohistochernistry. The correlation was analyzed by SPSS software using Spearman methods. As expected, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, compared to that of control, and was consistent with that of TPO, CD56, Galectin-3, MC, CK19 and B-raf. In addition, expres- sion of hsa-miR-200a-5p showed negative correlation to that of TPO \((r_s = -0.734; **: P < 0.01)\) and CD56 \((r_s = 0.570; **: P < 0.01)\), but positive correlation to that of Galectin-3 \((r_s = 0.601; **: P < 0.01)\), MC \((r_s = 0.508; **: P < 0.01)\), CK19 \((r_s = 0.712; **: P < 0.01)\) and B-raf \((r_s = 0.378; **: P < 0.01)\). PTC and papillary benign thyroid papillary hyperplasia are difficult to dis- tinguish in morphology, so requiring immunohistochernistry to further differentiate the diagno- sis, however, for the existing clinical common diagnostic marker for immunohistochernistry, the sensitivity and accuracy are low, it is easy to miss diagnosis. Therefore, there is an urgent need for a rapid and sensitive molecular marker. So miR-200a-5p can be used to assist in the diag- nosis of PTC at the molecular level, and as a biomarker, can be effectively used to distinguish between PTC and benign thyroid tumor with papillary hyperplasia.

PLOS ONE | https://doi.org/10.1371/journal.pone.0200290 | July 13, 2018 | 1/12
Introduction

Thyroid carcinoma is the most common endocrine cancer with a significantly increase of the incidence in recent years, especially in young men [1–7]. According to the histogenesis and morphology, thyroid carcinomas can be classified into papillary thyroid carcinoma (PTC) [8], follicular carcinoma [9], medullary carcinoma [10] and undifferentiated carcinoma [11]. PTC is the most common thyroid malignant tumor, generally with an indolent clinical course, accounting for about 60% to 70% of total thyroid cancers, [12–14]. The overall 5-year relative survival rate has been reported as high as 97.5%, and only a small percentage of papillary carcinomas show aggressive clinical behavior [12–13, 15–18]. Typical PTC is characterized by papillary structures with characteristic nuclear morphology, such as glassy nuclei, nuclear grooves, and intranuclear inclusions. But it is difficult to distinguish from thyroid benign lesions, such as nodular goiter, Hashimoto’s thyroiditis, and thyroid adenoma with papillary growth. At present, there are some markers for the differential diagnosis of PTC and benign thyroid tumor with papillary hyperplasia, such as CK19/Galectin-3/HBME1, but they are limited in clinical use because of their relative lower sensitivity and specificity. So it remains difficult in the differential diagnosis[19]. With the development of molecular biology and the emergence of various biomarkers, many researchers try to find new molecular biomarkers for early diagnosis and evaluation of prognosis of thyroid cancers.

MicroRNA (miRNA) are small non-coding RNA, approximately 18–22 nucleotide, and can post-transcriptionally regulate gene expression by binding to 3′-untranslated region of mRNAs, regulating target mRNAs transcript degradation or translational repression, and then extensively regulating biological functions, including tumorigenesis and development [20–23]. In addition, many researchers have reported the integrated genomic characterization, microRNA, gene expression and transcription factors signature of papillary thyroid carcinoma, and confirmed the correlation between PTC and microRNA [24–26]. Hsa-miR-200 family is a hot topic in recent years, which includes 5 members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) located on two different genomic clusters: one cluster including miR-200a, miR-200b and miR-429 on chromosome 1, and another cluster including miR-200c and miR-141 on chromosome 12[27–28]. Hsa-miR-200a, as one of its important members, has begun to attract much more attention since studies showed that hsa-miR-200a could inhibit the occurrence of renal cell carcinoma by inducing cell apoptosis through directly targeting SIRT1 [29–30]. It can regulate the endometrial cancer cell growth in vitro by targeting phosphatase and tensin homolog (PTEN) [31–32]. In addition, in tumorigenesis of colorectal cancer, hsa-miR-200a can target PTEN to promote colorectal cancer development. Chen et al, found that the low expression of hsa-miR-200a in hepatocellular carcinoma cells, and it could inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells by targeting FOX2, suggesting that miR-200a might be used as a therapeutic molecule for liver cancer[33]. Furthermore, the miR-200 family can regulate the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells [34]. A previous study by members of the research group found that the expression of miR-200a was positively correlated with the degree of tumor differentiation in colorectal cancer, but not with age, gender, tumor size, tumor invasion depth, lymph node metastasis, and TNM stage[35]. miRNA precursors that generate two kinds of abundant miRNAs by instance such mature sequences are denoted the miR-5p (5′arm) and miR-3p (3′arm) [36]. For miR-200a-5p, one study found miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[37]. Because the diagnose between benign and malignant thyroid tumors with papillary structure is easy to confuse, and our preliminary experiments showed that the expression of miR-200a-5p was higher in papillary thyroid carcinoma than in...
papillary thyroid tissue, so we want to explore whether miR-200a can be used as a new marker for the diagnosis of benign and malignant thyroid tumors with papillary structure. In our tests, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, consistent with that of TPO, CD56, Glectin-3, MC, CK19 and B-raf, which provides an experimental evidence for the possible diagnosis and treatment of PTC with hsa-miR-200a-5p.

Materials and methods

Specimens

In this study, 28 papillary benign thyroid tumors with papillary hyperplasia (as a control) and 40 thyroid carcinomas (PTC) patients were selected, which were surgical specimen at The Second Affiliated Hospitals of Anhui Medical University (Hefei, China) between 2015 and 2016. Patients who had been administered either chemotherapy or radiation therapy before surgery were excluded. The diagnoses were made according to the 2017 World Health Organization (WHO) classification of tumors, and were confirmed by permanent histology. The use of patient samples was approved by The Biomedical Ethics Committee of Anhui Medical University, with requirement of written informed consent from each patient (institutional review board-approved protocol number: 20180283).

Immunohistochemistry (IHC)

The aforementioned papillary benign thyroid tumor with papillary hyperplasia and thyroid carcinoma tissues were fixed and sliced to perform IHC staining according to the manufacturer’s instruction. Endogenous peroxidase was inactivated by incubating the sections in 3% H$_2$O$_2$ for 30 min. The sections were subjected to sequential incubations with 10% normal goat serum in 0.01 M PBS for 30 min at room temperature, and then respectively incubated in mouse TPO antibody (MAB-0630, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse CD56 antibody (Kit-0028, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse Galectin-3 antibody (MAB-0572, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse MC antibody (MAB-0130, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse CK19 antibody (KIT-0030, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China) and mouse B-raf V600E antibody (790–4855, 1:500, Roche, USA) in PBS containing 0.3% Triton X-100 overnight at 4°C. The sections were washed three times with PBS for 5 min each and then incubated with peroxidase-conjugated goat anti-mouse IgG (1: 200; Zymed, South San Francisco, CA, USA) for 1 hrs at room temperature. Finally, the sections were developed with DAB in 0.1 M Tris-buffered saline (TBS) containing 0.001% H$_2$O$_2$ for 30 min. The sections were observed under a microscope (Olympus, Tokyo, Japan), and five specific areas in each region were captured, and 10% or more was used as a cut-off line for positive in the slide evaluation.

In situ hybridization

The aforementioned tissues were fixed and sliced to perform in situ hybridization staining, according to the manufacturer’s instructions. The DNA sequence of the hybridization probe is 5’-TCCAG CACTG TCCGG TAAGA TG-3’. Slides were baked at 60°C oven for 2 hrs followed by de-waxing and hydration. Endogenous peroxidase was inactivated by incubating the sections in 3% H$_2$O$_2$ for 30 min. Added a total of 1 ml pepsase, which was diluted with 3% citric acid, and digested for 30 min at 37°C, and then washed with PBS for 3 times (5 min / time). Section was fixed by 1% paraformaldehyde / 0.1 M PBS (pH = 7.2–7.6) at room temperature for 10 min, including 1‰ DEPC, and washed by ddH$_2$O for 3 times (5 min / time). Subsequently, added a
total of 20 μl pre-hybridization solution, and incubated at 42˚C for 2 hrs, and then hybridized with 20 μl pre-hybridization solution, and incubated at 42˚C overnight. Then, sections were washed by 2×SSC solution at 37˚C for 2 times (5 min / time), and then washed by 0.5×SSC solution at 37˚C for 15 min, and also washed by 0.2×SSC solution at 37˚C for 15 min. Dropwise add blocking solution, and incubated at 37˚C for 30 min, and then added biotinylation mouse antidigoxin, and incubated at 37˚C for 60 min with PBS washing for 4 times (5 min / time). SABC was added drop by drop and incubated at 37˚C for 20 min with PBS washing for 3 times (5 min / time), and then added biotinylation peroxidase, and incubated at 37˚C for 20 min with PBS washing for 3 times (5 min / time). Developed in 50 μl DAB solution for 10 min, and washed with ddH_2O followed by re-dyeing with hematoxylin. The sections were observed under a microscope (Olympus, Tokyo, Japan), and five specific areas in each region were captured, and 10% or more was used as a cut-off line for positive in the slide evaluation.

Quantitative real time polymerase chain reaction (qRT-PCR) assay
The total RNA of fresh tissue was extracted using the phenol-chloroform method, was reversely transcribed with a Reverse Transcription Kit (Takara, Japan) according to the manufacturers’ instructions. The reaction mixture, including 2 μl 5 × RT buffer, 0.5μl RT Enzyme Mix, 0.5μl P-primer, 500 ng total RNA, RNase Free ddH_2O up to 10 μl, was prepared and reacted at 37˚C for 15 min, followed by 95˚C for 5min, and then 4˚C hold. Reverse transcription reactions were performed using qRT-PCR kit (Takara) according to the manufacturers’ instructions. The reaction mixture, including 10 μl of 2 × SYBR Premix Ex Taq II, 0.8 μl of forward primer, 0.8 μl of reverse primer, 0.4 μl of ROX Reference Dyell, 2 μl of cDNA and 6 μl of ddH_2O, was prepared, and the qRT-PCR was performed according to the following program: one cycle of 95˚C for 30 s; 40 cycles of 95˚C for 5 s, 60˚C for 34 s, and 4˚C hold. Finally, the data was analyzed using the SDS 1.4 software (Applied Biosystems) based on 2^\(-\Delta\Delta\text{Ct}\), and histogram analysis was performed using the Origin 9.0 software.

Statistical analysis
All statistical analyses were performed using SPSS software system for Windows (version 22.0; SPSS, Chicago, IL). Spearman co-efficient was calculated to determine the correlation between the expression of PTC and established biomarkers, such as hsa-miR-200a-5p, TPO, CD56, Glectin-3, MC, CK19 and B-raf. \(p < 0.05\) and \(p < 0.01\) were considered as significant differences and highly significant differences, respectively.

Results
The hsa-miR-200a-5p expressive level was significantly increased in papillary thyroid carcinoma patients
As in Fig 1 and Table 1, when compared to control, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, consistent with that of Galectin-3, MC, CK19 and B-raf. However, the expressive level of TPO and CD56 was significantly decreased.

The hsa-miR-200a-5p expressive level was significantly increased in papillary thyroid carcinoma patients fresh tissue
As exhibiting of Fig 2, the expression level of hsa-miR-200a-5p was significantly increased in fresh tissue of PTC patients (mean = 6.767, n = 40), when compared to that of control (mean = 1.402, n = 28) (\(**: p < 0.01\)).
The hsa-miR-200a-5p expression showed positive correlation to that of galectin-3, MC, CK19 and B-raf, and negative correlation to that of TPO and CD56 in papillary thyroid carcinoma.

In Table 2, by SPSS software using Spearman method for correlation analysis, the hsa-miR-200a-5p expression showed negative correlation to that of TPO and CD56, with coefficients of correlation (rho) -0.734 and -0.570 (**: p < 0.01) respectively, and showed positive correlation to that of Galectin-3, MC, CK19 and B-raf, with the coefficients of correlation (rho) 0.601, 0.508, 0.712 and 0.378 (**: p < 0.01) respectively.

Discussion

Here, we demonstrated that the expressive level of hsa-miR-200a-5p was significantly increased in the PTC, compared to that of control. It was negatively correlated to the expressions of TPO and CD56, with coefficients of correlation (rho) -0.734 and -0.570 (**: p < 0.01) respectively, while positively correlated to the Galectin-3, MC, CK19 and B-raf, with coefficients of correlation (rho) 0.601, 0.508, 0.712 and 0.378 (**: p < 0.01) respectively. In addition,
for the existing clinical common diagnostic marker for immunohistochemistry, the sensitivity and accuracy are low, it is easy to miss diagnosis. Therefore, there is an urgent need for a rapid and sensitive molecular marker. Therefore, miR-200a-5p can be used to assist in the diagnosis of PTC at the molecular level, and as a biomarker, can be effectively used to distinguish between PTC and benign thyroid tumor with papillary hyperplasia.

Identification of new and sensitive biomarkers is still a priority to improve differential diagnosis of papillary thyroid carcinoma (PTC) and benign thyroid tumor. Although Galectin-3 and MC are frequently expressed in PTC [38], and TPO and CD56 are frequently expressed in benign thyroid tumor [39], the sensitivity of these markers remains unsatisfactory. For example, TPO is the key enzyme for the synthesis of thyroxin (T3, and T4), and plays an important role in the processes of activation of iodine, iodization of tyrosine residues, and coupling of iodinated tyrosine residues [40–41]. In recent years, scholars have begun to study the table of TPO in the transformation of thyroid adenopathy and explore its practical value, but the conclusion is still in dispute. The majority of reports indicate that TPO is in low form or lack of expression in thyroid malignant tumor [42], and TPO immunostaining has higher sensitivity and specificity to distinguish thyroid benign and malignant disease [43–44]. CD56 is a member of the immunoglobulin superfamily, and the significance of its expression on malignant tumors, such as small cell lung cancer [45], thyroid gland tumor [46] and prostate cancer is still being studied [47]. Similar to TPO, CD56 is in low form or lack of expression in PTC, but has a higher expression in normal thyroid tissue, such as follicular adenoma, nodular goiter and papillary hyperplasia. Galectin-3 is a β-galactose binding protein, which may participate the process of the cell growth, adhesion, inflammation, immune-regulation and apoptosis, and

Table 1. The expressive levels of miR-200a-5p, TPO, CD56, Galectin-3, MC, CK19 and B-raf in benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.

| Expressive levels | Tumor types | Benign thyroid tumor with papillary hyperplasia (n = 28) | Papillary thyroid carcinoma (n = 40) |
|-------------------|-------------|--------------------------------------------------------|-----------------------------------|
| miR-200a-5p       | Positive, n (%) | 5 (17.86) | 35 (87.50)** |
|                   | Negative, n (%) | 23 (82.14) | 5 (12.50) |
| TPO               | Positive, n (%) | 28 (100)  | 3 (7.50)   |
|                   | Negative, n (%) | 0 (0.00)   | 37 (92.50)** |
| CD56              | Positive, n (%) | 24 (85.72) | 0 (0.00)  |
|                   | Negative, n (%) | 4 (14.28)  | 40 (100)** |
| Galectin3         | Positive, n (%) | 3 (10.72)  | 40 (100)** |
|                   | Negative, n (%) | 25 (89.28) | 0 (0.00)  |
| MC                | Positive, n (%) | 5 (17.86)  | 39 (97.50)** |
|                   | Negative, n (%) | 23 (82.14) | 1 (2.50)   |
| CK19              | Positive, n (%) | 13 (46.43) | 40 (100)** |
|                   | Negative, n (%) | 15 (53.57) | 0 (0.00)  |
| B-raf             | Positive, n (%) | 0 (0.00)   | 32 (80.00)** |
|                   | Negative, n (%) | 28 (100)   | 8 (20.00)  |

Note
**P < 0.01.
TPO, thyroid peroxidase
CD56, cluster of differentiation 56
MC, mesothelial cell
CK19, cytokeratin 19
B-raf, BRAF.

https://doi.org/10.1371/journal.pone.0200290.t001
therefore associated with the formation and metastasis of many tumors, such as colon cancer and PTC [48–49]. In current application, Mesothelial cell (MC) is a mesothelioma related antigen, and has been used as an immunogen to produce monoclonal antibody. The MC was strongly expressed in mesothelioma and has been used in thyroid pathology diagnosis as well [50]. The high expression of MC in thyroid carcinoma appears to be a good marker for thyroid papillary carcinoma. BRAF somatic mutations, was the most extensively investigated molecular markers and common genetic alterations in PTC [51]. Many studies have found that higher expression of Braf mutant protein can predict aggressive tumor behavior in PTC, and BRAF V600E IHC has high practical value for the detection of the BRAF V600E mutation in primary and metastatic PTC [52–53]. Furthermore, the results of several studies have challenged the notion that the BRAFV600E mutation is a valuable prognostic marker. The sensitivity and specificity of TPO, CD56, Galectin-3, MC, CK19 and B-raf, as existing common biomarkers, were still too limited and unsatisfactory to be widely used in clinical diagnosis.

Fig 2. Expression level of hsa-miR-200a-5p in PTC by qRT-PCR. The expression level of hsa-miR-200a-5p in PTC fresh tissue was significantly increased compared with the control.

https://doi.org/10.1371/journal.pone.0200290.g002
miRNAs are no-coding RNAs with a length of 18–24 nt, and could be down-regulated the target gene expression at transcriptional and translational levels. As in several previous documented studies, some miRNAs might be involved in the regulation of biological processes that are important for cancer cells, which indirectly promote the functions of oncogene and tumor suppressors [54–55]. For instance, hsa-miR-200a-5p, as an important members of miR-200 family, has been paid more attention recently. Many studies showed that the high expression of hsa-miR-200a-5p was present in a variety of cancers, including colorectal cancer, pancreatic cancer, esophageal adenocarcinoma, but remains unclear in thyroid neoplasms. Herein, we evaluated the hsa-miR-200a-5p expression in papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia using formalin-fixed paraffin-embedded samples. Our data demonstrated that the expression of hsa-miR-200a-5p increased significantly in PTC. In comparison with other established biomarkers for PTC, the expression rate of hsa-miR-200a-5p was higher than that of Galectin-3 and MC, and therefore can be in differential diagnosis between PTC and benign thyroid tumors. In addition, according to the correlation, we found that hsa-miR-200a-5p was negatively correlated to TPO ($r_s = -0.734$; **: $P < 0.01$) and CD56 ($r_s = -0.570$; **: $P < 0.01$), while hsa-miR-200a-5p was positively correlated to Galectin-3 ($r_s = 0.601$; ***: $P < 0.01$), MC ($r_s = 0.508$; ***: $P < 0.01$), CK19 ($r_s = 0.712$; ***: $P < 0.01$) and B-raf ($r_s = 0.378$; **: $P < 0.01$). The above results indicated that hsa-miR-200a-5p, as a biomarker, can be effectively used to distinguish between papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia.

In conclusion, this study firstly demonstrated that hsa-miR-200a-5p is a sensitive and specific biomarker for PTC with potential clinical application in the differential diagnosis between benign and malignant thyroid tumors, as well as basic and clinical-oriented researches. However, the mechanism is not clear. In the future, we will focus on these studies, and strengthen the proof of hsa-miR-200a-5p as a new biomarker to distinguish between papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia, and other clinical diagnoses.

**Acknowledgments**

28 patients with papillary benign thyroid tumors with papillary hyperplasia and 40 patients with PTC selected from The Second Affiliated Hospitals of Anhui Medical University (Hefei, China) between 2015 and 2016.

---

Table 2. Correlation analysis of the expressions of hsa-miR-200a-5p to TPO, CD56, Galectin-3, MC, CK19 and B-raf in papillary thyroid carcinoma.

| Index                                           | n   | TPO | CD56 | Galectin-3 | MC   | CK19 | B-raf |
|------------------------------------------------|-----|-----|------|------------|------|------|-------|
| Benign thyroid tumor with papillary hyperplasia | 28  | +   | -    | +          | +    | +    | -     |
| Papillary thyroid carcinoma                    | 40  | +   | 34** | 0          | 35** | 0    | 35**  |

Note: TPO, thyroid peroxidase; CD56, cluster of differentiation 56; MC, mesothelial cell; CK19, cytokeratin 19.

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = -0.734$

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = -0.570$

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = 0.601$

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = 0.508$

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = 0.712$

**: Correlated to miR-200a-5p. $P < 0.01$, $r_s = 0.378$. 

https://doi.org/10.1371/journal.pone.0200290.1002
Author Contributions

Conceptualization: Xiaocan Li, Zhengsheng Wu.
Data curation: Shan Huang, Qiang Wu.
Methodology: Dongrui Jiang, Hongzhen Yu.
Writing – original draft: Xian Wang.
Writing – review & editing: Chaobing Gao, Zhengsheng Wu.

References

1. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5 [J]. European Journal of Cancer, 2017, 77:140–152. https://doi.org/10.1016/j.ejca.2017.02.023 PMID: 28410490

2. Khan NE, Bauer AJ, Schultz KAP, Doros L, Decastro RM, Ling A, et al. Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.[J]. Journal of Clinical Endocrinology & Metabolism, 2017, 102(5):1614–1622.

3. Formiga M N, de Andrade K C, Kowalski L P, Achatz M I. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome[J]. Jama Oncology, 2017, 3(10):1400–1402. https://doi.org/10.1001/jamaoncol.2016.6389 PMID: 28114597

4. Locofo C, Galeone C, Sacchettini C, et al. Second malignancy risk in patients with bronchopulmonary carcinoids: epidemiological results from Italian Network of Cancer Registries.[J]. Tumori, 2017, 103(2): p. e15–e20. https://doi.org/10.5301/tj.5000598 PMID: 28106244

5. Šafraňek J, Třeská V, Skalič ký T, Špidlen V, Doležal J, Kubáčková D, et al. [Thyroid carcinoma, ten-years file][J]. Rozhl Chir, 2016, 95(11):394–397. PMID: 28033017

6. Aboosha hab R, Yaghmaei P, Ghadakza h HG, Hedayati M. Lack of Association between Serum Adiponectin/Lep tin Levels and Medullary Thyroid Cancer.[J]. Asian Pac J Cancer Prev, 2016, 17(8):3861–3864. PMID: 27644630

7. Uchino S, Ishikawa H, Miyau chi A, Hirokaw a M, Noguchi S, Usha m a M, et al. Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis[J]. J Clin Endocrinol Metab, 2016, 101(12):jc.2016–2043.

8. An H J, Ko G H, Lee J H, Lee J S, Kim D C, Yang J W, et al. Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med, 2017, 52(1): 9–13. https://doi.org/10.4132/jptm.2017.07.26 PMID: 28994272

9. Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, et al. Reintroducing the sodium iodide symporter (NIS) to anaplastic thyroid carcinoma.[J]. Thyroid Official Journal of the American Thyroid Association, 2017, 27(12):1534–1543. https://doi.org/10.1089/thy.2017.0290 PMID: 29032724

10. Roman B R, Morris L G, Davies L. The thyroid cancer epidemic, 2017 perspective[J]. Current Opinion in Endocrinology Diabetes & Obesity, 2017, 24(5):332–336. https://doi.org/10.1097/MED.0b013e3280109b6c

11. Lee D Y, Won J K, Choi H S, Park do J, Jung K C, Sung M W, et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma[J]. Thyroid Official Journal of the American Thyroid Association, 2016; 26(9):1259–1268. https://doi.org/10.1089/thy.2016.0147 PMID: 27412715

12. Geller G, Laskin J, Cheung W Y, Ho C, et al. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy[J]. Thyroid Research, 2017; 10(1):6. https://doi.org/10.1096/st13044-017-0941-6 eCollection 2017. PMID: 28932277

13. Lmz M, Pkr M. Medullary thyroid carcinoma—Adverse events during systemic treatment: risk-benefit ratio[J]. Arch Endocrinol Metab, 2017; 61(4):398–402. https://doi.org/10.1590/2359-3997000000267 PMID: 28658345

14. Vuong H G, Kondo T, Oishi N, Nakazawa T, Mochizuki K, Miyau chi A, et al. Pediatric follicular thyroid carcinoma—indolent cancer with low prevalence of RAS mutations and absence of PAX8-PPARG fusion in a Japanese population[J]. Histopathology, 2017; 71(5):760–768. https://doi.org/10.1111/his.13285 PMID: 28621837

15. Xu B, Ghossein R. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management[J]. European Journal of Surgical Oncology the Journal of the European Society of Surgical Oncology & the British Association of Surgical Oncology, 2018; 44(3):338–347.
32. Li R, He J L, Chen X M, Long C L, Yang D H, Ding Y B, et al. MiR-200a is involved in proliferation and Yoneyama K, Ishibashi O, Kawase R, Kurose K, Takeshita T. miR-200a, miR-200b and miR-429 are
31. Zhang Z, Liu Z B, Ren W M, Ye X G, Zhang Y Y. The miR-200 family regulates the epithelial-mesenchyme-
33. Chen S, Ma D, Chen Q, Zhang J J, Tian Y R, Wang Z C, et al. MicroRNA-200a inhibits cell growth and
30. Gao C, Peng F H, Peng L K. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and
29. Xiao H, Tang K, Liu P, Chen K, Hu J H, Zeng J, et al. LncRNA MALAT1 functions as a competing endog-
28. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
27. Zhang J, Liu Y, Liu Z, Wang X M, Yin D T, Zheng L L, et al. Differential Expression Profiling and Functional Analysis of microRNAs through Stage I-III Papillary Thyroid Carcinoma [J]. International Journal of Medical Sciences, 2013, 10(5):585–592. https://doi.org/10.7150/ijms.5794 PMID: 23533107
26. Zhang J, Liu Y, Liu Z, Wang X M, Yin D T, Zheng L L, et al. Differential Expression Profiling and Functional Analysis of microRNAs through Stage I-III Papillary Thyroid Carcinoma [J]. International Journal of Medical Sciences, 2013, 10(5):585–592. https://doi.org/10.7150/ijms.5794 PMID: 23533107
25. Murali N S A, Othman S N, Yusof A M, Suhaimi S N A, Muhammad R, Jamal R. Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis[J]. Peerj, 2016, 4: e2119. https://doi.org/10.7717/peerj.2119
24. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
23. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
22. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
21. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
20. Wu W. MicroRNA, Noise, and Gene Expression Regulation[M]// MicroRNA and Cancer. 2018; 1699: p. 91–96.
19. Prasad M L, Huang Y, Pellegata N S, de la Chapelle A, Kloos RT. Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC[J]. Histopathology, 2004, 45(1):39–46. https://doi.org/10.1111/j.1365-2559.2004.01876.x PMID: 15228442
18. Wong K S, Angell T E, Strickland K C, Alexander E K, Cibas E S, Krane J F et al. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier[J]. Thyroid Official Journal of the American Thyroid Association, 2016; 26(7):911–915. https://doi.org/10.1089/thy.2015.0644 PMID: 27219469
17. Kim S H, Roh J L, Gong G, Cho K J, Choi S H, Nam S Y, et al. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-up.[J]. Thyroid Official Journal of the American Thyroid Association, 2016, 26(10):1472–1479. https://doi.org/10.1089/thy.2016.0236 PMID: 27457917
16. Wong K S, Angell T E, Strickland K C, Alexander E K, Cibas E S, Krane J F et al. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier[J]. Thyroid Official Journal of the American Thyroid Association, 2016; 26(7):911–915. https://doi.org/10.1089/thy.2015.0644 PMID: 27219469
15. Sun J, Li H, Yin Y, Pathology D, University A M. Expression of miR-200a in colorectal carcinoma and its clinical significance[J]. Acta Universitatis Medicinalis Anhui, 2015.
14. Wu W. MicroRNA, Noise, and Gene Expression Regulation[M]// MicroRNA and Cancer. 2018; 1699:67–74. https://doi.org/10.1007/978-1-4939-7435-1_4 PMID: 29086365
13. Sun J, Li H, Yin Y, Pathology D, University A M. Expression of miR-200a in colorectal carcinoma and its clinical significance [J]. Acta Universitatis Medicinalis Anhui, 2015.
12. Prasad M L, Huang Y, Pellegata N S, de la Chapelle A, Kloos RT. Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC[J]. Histopathology, 2004, 45(1):39–46. https://doi.org/10.1111/j.1365-2559.2004.01876.x PMID: 15228442
11. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular Biology, 2018, 1699:83–89. https://doi.org/10.1007/978-1-4939-7435-1_6 PMID: 29086370
10. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
9. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
8. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular
7. Lee J S, Ahn Y H, Won H S, Sun D S, Kim Y H, Ko Y H, et al. Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis:[J]. BioMed Research International, 2017, (2017-02-22), 2017, 2017(3):1–11.
6. Senfter D, Madlener S, Krupitza G, Mader R M. The microRNA-200 family: still much to discover.[J]. Biomol Concepts, 2016, 7(5–6):311–319. https://doi.org/10.1515/bmc-2016-0020 PMID: 27837593
5. Xiao H, Tang K, Liu P, Chen K, Hu J H, Zeng J, et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma[J]. Oncotarget, 2015, 6(35):38005–38015. https://doi.org/10.18632/oncotarget.5357 PMID: 26461224
4. Gao C, Peng F H, Peng L K. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1[J]. Neoplasma, 2014, 61(6):680–689. https://doi.org/10.4149/neop_2014_083 PMID: 25150313
3. Yoneyama K, Ishibashi O, Kawase R, Kurose K, Takeshita T. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma[J]. Anticancer Research, 2015, 35(3):1401–1410. PMID: 25750291
36. Yang X, Du W W, Li H, Liu F, Khorshidi A, Rutnam Z J, et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion.[J]. Nucleic Acids Research, 2013, 41(21):9686–9704. https://doi.org/10.1093/nar/gkt680 PMID: 23990326

37. Wang Y, Qiu C, Lu N, Liu Z, Jin C, Sun C, et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.[J]. International Journal of Oncology, 2018, 52(6):2130–2142. https://doi.org/10.3892/ijo.2018.4359 PMID: 29620165

38. Galusca B, Durnollard J M, Lassandre S, Niveloua A, Prades J M, Estour B, et al. Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.[J]. Vircrorns Archiv, 2005, 447(1):18–23. https://doi.org/10.1007/s00428-005-1268-5 PMID: 15891902

39. Delivianis D A, Gustafson M P, Bornschlegl S, Merten M M, Kottscade L, Withers S, et al. Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms.[J]. J Clin Endocrinol Metab, 2017, 102(8):2770–2780. https://doi.org/10.1210/jc.2017-00448 PMID: 2869832

40. Hou X, Han R, Tian Y, Xie W, Sun G, Li G, et al. Cloning of TPO gene and associations of polymorphisms with chicken growth and carcass traits.[J]. Molecular Biology Reports, 2013, 40(4):3437–3443. https://doi.org/10.1007/s11033-012-2421-2 PMID: 23275198

41. Lamas L, Taurog A. The importance of thyroglobulin structure in thyroid peroxidase-catalyzed conversion of diiodo tyrosine to thyroxine.[J]. Endocrinology, 1977, 100(4):1129–1136. https://doi.org/10.1210/endo-100-4-1129 PMID: 837878

42. Gabriac F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, et al. Impact of Hashimoto’s thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence[J]. Endokrynologia Polska, 2016, 67(1):48–53. https://doi.org/10.5603/EP.a2016.0022 PMID: 26894115

43. Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius H J, Remmelink M, et al. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.[J]. Oncology Letters, 2017, 14(4):4183–4189. https://doi.org/10.3892/ol.2017.6719 PMID: 28943926

44. Hopera V, Larin A, Jensen K, Bauer A, Vasko V. Thyroid Fine Needle Aspiration Biopsies in Children: Study of Cytological-Histological Correlation and Immunostaining with Thyroid Peroxidase Monoclonal Antibodies.[J]. International Journal of Pediatric Endocrinology, 2010, 2010(1):690108.

45. Wang X., Zhang Y, Hu M, Wang R T, Liu L, Qian K, et al., [Prognostic and Predictive Value of Thyroid Antibodies]. Zhongguo Fei Ai Za Zhi, 2017. 20(8): p. 522–527. https://doi.org/10.3779/j.issn.1009-3419.2017.08.04 PMID: 28855032

46. Dunderovic D, Lipkovski J M, Boricic I, Soldatovic I, Bozic V, Cvejic D, et al. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.[J]. Diagnostic Pathology, 2015, 10(1):196. https://doi.org/10.1186/s13000-015-0428-4 PMID: 26503236

47. Kryvenko O N, Williamson S R, Trpkov K, Gupta N S, Athanazio D, Selig N K, et al. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.[J]. Vircrorns Archiv, 2016, 470(1):47–54. https://doi.org/10.1007/s00428-016-2033-7 PMID: 27743032

48. Hao M, Li M, Li W. Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension.[J]. Molecular Medicine Reports, 2017, 15(1):160–168. https://doi.org/10.3892/mmr.2016.6020 PMID: 27959409

49. Tsai H F, Wu C S, Chen Y L, Liao H J, Chyuau I T, Hsu PN. Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.[J]. Journal of Molecular Medicine, 2016, 94(5):545–556. https://doi.org/10.1007/s00109-015-1368-x PMID: 26631140

50. Ricciuti B, Metro G, Leonardi G C, Sordo R D, Colella R, Puma F, et al. Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.[J]. Tumori, 2016, 102(Suppl. 2). https://doi.org/10.1007/8500-010-01210/endo-100-4-1129 PMID: 837878

51. Chai Y J, Min W Y, Jee H G, Kim Y A, Kim J H, Xing M, et al. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.[J]. Plos One, 2016, 11(7):e0159235. https://doi.org/10.1371/journal.pone.0159235 PMID: 27410688

52. Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie J B, Heller K S, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.[J]. Surgery, 2013, 154(6):1199–1204. https://doi.org/10.1016/j.surg.2013.06.020 PMID: 23931769

53. Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, et al. Specific immunohistochemical detection of the BRAF-V600E mutation in primary and metastatic papillary thyroid carcinoma.[J]. Experimental & Molecular Pathology, 2016, 100(1):236–241.
54. Zhang J, Li Y, Dong M, Wu D. Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer[J]. Oncology Letters, 2017, 14(4):4983–4988. https://doi.org/10.3892/ol.2017.6769 PMID: 29085511

55. Bobbili M R, Mader R M, Grillari J, Dellago H. OncomiR-17-5p: alarm signal in cancer?[J]. Oncotarget, 2017, 8(41):71206–71222. https://doi.org/10.18632/oncotarget.19331 PMID: 29050357